These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9881496)

  • 1. Diffuse mucosal damage in the large intestine associated with Irinotecan (CPT-11).
    Duong Van Huyen JP; Bloch F; Attar A; Levoir D; Kreft C; Molina T; Bruneval P
    Dig Dis Sci; 1998 Dec; 43(12):2649-51. PubMed ID: 9881496
    [No Abstract]   [Full Text] [Related]  

  • 2. Irinotecan (CPT-11) induced colitis: report of a case and review of Food and Drug Administration MEDWATCH reporting.
    Sears S; McNally P; Bachinski MS; Avery R
    Gastrointest Endosc; 1999 Dec; 50(6):841-4. PubMed ID: 10570349
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11).
    Boisseau M; Bugat R; Mahjoubi M
    Eur J Cancer; 1996 Apr; 32A(4):737-8. PubMed ID: 8695285
    [No Abstract]   [Full Text] [Related]  

  • 4. Phlebitis due to irinotecan.
    Tas F; Karagol H; Karadeniz A; Topuz E
    Clin Oncol (R Coll Radiol); 2003 May; 15(3):167. PubMed ID: 12801060
    [No Abstract]   [Full Text] [Related]  

  • 5. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.
    Gibson RJ; Bowen JM; Inglis MR; Cummins AG; Keefe DM
    J Gastroenterol Hepatol; 2003 Sep; 18(9):1095-100. PubMed ID: 12911669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An autopsy case of acute pulmonary toxicity related to irinotecan.
    Ruiz-Casado A; Castellano V; Moreno F
    Clin Transl Oncol; 2008 Sep; 10(9):597-8. PubMed ID: 18796380
    [No Abstract]   [Full Text] [Related]  

  • 7. Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction.
    Ong SY; Clarke SJ; Bishop J; Dodds HM; Rivory LP
    Anticancer Drugs; 2001 Aug; 12(7):619-25. PubMed ID: 11487719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re:Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
    Guffroy M; Hodge T
    J Natl Cancer Inst; 1996 Sep; 88(17):1240-1. PubMed ID: 8780636
    [No Abstract]   [Full Text] [Related]  

  • 9. Irinotecan-induced dysarthria.
    Baz DV; Bofill JS; Nogueira JA
    J Natl Cancer Inst; 2001 Sep; 93(18):1419-20. PubMed ID: 11562394
    [No Abstract]   [Full Text] [Related]  

  • 10. Thalidomide and irinotecan-associated diarrhea.
    Tchekmedyian NS
    Am J Clin Oncol; 2002 Jun; 25(3):324. PubMed ID: 12040298
    [No Abstract]   [Full Text] [Related]  

  • 11. Central nervous system toxicity induced by irinotecan.
    Hamberg P; Donders RC; ten Bokkel Huinink D
    J Natl Cancer Inst; 2006 Feb; 98(3):219. PubMed ID: 16449682
    [No Abstract]   [Full Text] [Related]  

  • 12. Phospholipid fatty acid composition and diamine oxidase activity of intestinal mucosa from rats treated with irinotecan hydrochloride (CPT-11) under vegetable oil-enriched diets: comparison between perilla oil and corn oil.
    Usami M; Ohata A; Kishimoto K; Ohmae K; Aoyama M; Miyoshi M; Fueda Y
    JPEN J Parenter Enteral Nutr; 2006; 30(2):124-32. PubMed ID: 16517957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018).
    Lam W; Jiang Z; Guan F; Hu R; Liu SH; Chu E; Cheng YC
    BMC Complement Altern Med; 2014 Dec; 14():490. PubMed ID: 25510341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dysarthria during irinotecan administration].
    Ceccaldi B; Kara F; Mommeja-Marin H; Bègue M; Saint Blancard P; Le Marec E; Hauteville D
    Rev Med Interne; 2002 Nov; 23(11):950-1. PubMed ID: 12481397
    [No Abstract]   [Full Text] [Related]  

  • 15. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
    Emmink BL; Van Houdt WJ; Vries RG; Hoogwater FJ; Govaert KM; Verheem A; Nijkamp MW; Steller EJ; Jimenez CR; Clevers H; Borel Rinkes IH; Kranenburg O
    Gastroenterology; 2011 Jul; 141(1):269-78. PubMed ID: 21459094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic tumor rupture following effectual treatment with irinotecan in a patient with highly refractory malignant lymphoma.
    Tsutani H; Inai K; Kishi S; Morinaga K; Naiki H; Ueda T
    Int J Hematol; 1999 Oct; 70(3):178-80. PubMed ID: 10561911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
    Futatsuki K; Wakui A; Nakao I; Sakata Y; Kambe M; Shimada Y; Yoshino M; Taguchi T; Ogawa N
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1033-8. PubMed ID: 8210254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
    Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
    Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Three cases of liver metastasis of colon cancer responding to systemic combination chemotherapy utilizing CPT-11].
    Kobayashi A; Yamaguchi M
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2255-8. PubMed ID: 11142172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.
    Fittkau M; Voigt W; Holzhausen HJ; Schmoll HJ
    J Cancer Res Clin Oncol; 2004 Jul; 130(7):388-94. PubMed ID: 15160289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.